SkylineDx, a San Diego-based diagnostics company, has been named “Diagnostics Company of the Year” by BioTech Breakthrough for the second consecutive year, according to announcements published via Yahoo Finance and citybiz. The award recognizes the company’s work on tests that help guide treatment decisions in oncology and autoimmune disease.
SkylineDx operates a laboratory in the San Diego area and develops what the industry calls molecular diagnostics: tests that analyze genetic and protein markers to help physicians predict which patients are likely to progress and which treatments are most likely to work. Its commercially available products focus on melanoma staging and rheumatologic conditions, areas where treatment decisions hinge on precise risk assessment.
Repeat recognition from an awards program matters less for the trophy than for what it signals about scale. BioTech Breakthrough’s review process evaluates companies on product utility, market adoption and technological differentiation. A company winning twice in a row suggests its test volumes and clinical evidence base grew rather than plateaued between awards.
For San Diego’s life sciences cluster, the recognition adds to a strengthening year for the region’s diagnostics and tools segment. The city’s biotech economy remains anchored by the Torrey Pines corridor and UTC, where contract research organizations, genomics firms and diagnostics developers cluster around research institutions. Diagnostics companies occupy a distinctive niche: they generate recurring clinical revenue earlier than pure drug developers, which makes them more resilient when venture funding tightens, and they create steady laboratory jobs that don’t depend on a single clinical trial outcome.
The company traces its roots to the Netherlands and expanded its U.S. operations in San Diego, where it runs its clinical laboratory and commercial team. Its products are designed to be run on samples shipped from dermatology and rheumatology practices nationally, meaning the local lab functions as a processing hub for specimens from across the country.
The company’s flagship products illustrate the model. Its melanoma tests are designed to help dermatologists decide which early-stage patients need sentinel lymph node biopsies, reducing unnecessary procedures while catching progression earlier, and its rheumatology panels aim to predict which patients will respond to specific therapies before costly treatment cycles begin. That positioning, moving treatment decisions from trial-and-error toward evidence-based selection, is where diagnostics companies argue they deliver both better outcomes and lower total system costs, an argument that has grown louder as insurers scrutinize specialty drug spending. Clinical adoption at that scale depends on reimbursement coverage, which takes years to build test by test and payer by payer.
San Diego’s diagnostics sector has quietly become one of the region’s more consistent sources of biotech employment, with firms in molecular testing, spatial biology and companion diagnostics adding staff even when drug-development funding cycles cool. SkylineDx’s second straight award underscores that steadiness, and it positions the firm within the region’s narrative as it courts further life sciences investment against competing hubs in Boston and the Bay Area.
